News & Updates
Filter by Specialty:
Upadacitinib works in select ankylosing spondylitis patients
The Janus kinase inhibitor upadacitinib induces significantly higher response than placebo in ankylosing spondylitis patients with inadequate response to biological disease-modifying antirheumatic drugs, without introducing new safety signals, according to data from a phase III trial.
Upadacitinib works in select ankylosing spondylitis patients
14 Jul 2022
Ozoralizumab shows therapeutic potential in rheumatoid arthritis
Treatment with the next-generation anti-TNFα antibody yields marked improvements in the signs and symptoms of rheumatoid arthritis in patients with inadequate response to methotrexate (MTX), while having an acceptable safety profile, as shown in the phase II/III OHZORA trial.
Ozoralizumab shows therapeutic potential in rheumatoid arthritis
13 Jul 2022
RA patient’s perspective must be respected in treatment decisions, says study
Physician-reported measures on responses to tofacitinib and adalimumab treatments are higher than those reported by patients with rheumatoid arthritis (RA), according to a post hoc analysis of data from phase III and phase IIIb/IV trials.
RA patient’s perspective must be respected in treatment decisions, says study
07 Jul 2022
Distinct plasma vs gut microbiome seen in SLE patients, healthy individuals
A distinct community and greater heterogeneity have been observed in the plasma microbiome compared to the gut in both patients with systemic lupus erythematosus (SLE) and healthy individuals, reports a recent study. This suggests that the predominant circulating microbiome may originate from sites other than the gastrointestinal tract.
Distinct plasma vs gut microbiome seen in SLE patients, healthy individuals
03 Jul 2022
Gout patients endorse reasons for not taking allopurinol
Patients with gout who refuse to take allopurinol for their condition do so because of their desire to lead a normal life and to test whether they could reduce the dose without experiencing any symptoms, a recent study has found.
Gout patients endorse reasons for not taking allopurinol
02 Jul 2022
How safe for the heart is hydroxychloroquine use in RA patients?
The risks of sudden cardiac arrest or ventricular arrythmia (SCA/VA) and major adverse cardiovascular event (MACE) are comparable between methotrexate (MTX) and hydroxychloroquine (HCQ) in older patients with rheumatoid arthritis (RA), reports a study.
How safe for the heart is hydroxychloroquine use in RA patients?
01 Jul 2022
Do bDMARDs prevent osteoporotic fractures in RA patients?
Use of biological disease-modifying antirheumatic drugs (bDMARDs) appears to have no benefit in the prevention of osteoporotic fractures among patients with rheumatoid arthritis (RA), according to the results of a recent study.
Do bDMARDs prevent osteoporotic fractures in RA patients?
01 Jul 2022
Baricitinib delays, lowers frequency of flares in JIA
In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.